DOCSLIB.ORG

Combating Malignant Melanoma with the Multifaceted Soy-Dervied Peptide Lunasin." (2017)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Combating Malignant Melanoma with the Multifaceted Soy-Dervied Peptide Lunasin. University of Louisville ThinkIR: The University of Louisville's Institutional Repository Electronic Theses and Dissertations 5-2017 Combating malignant melanoma with the multifaceted soy- dervied peptide lunasin. Christopher Paul Shidal University of Louisville Follow this and additional works at: https://ir.library.louisville.edu/etd Part of the Medical Pharmacology Commons Recommended Citation Shidal, Christopher Paul, "Combating malignant melanoma with the multifaceted soy-dervied peptide lunasin." (2017). Electronic Theses and Dissertations. Paper 2713. https://doi.org/10.18297/etd/2713 This Doctoral Dissertation is brought to you for free and open access by ThinkIR: The University of Louisville's Institutional Repository. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of ThinkIR: The University of Louisville's Institutional Repository. This title appears here courtesy of the author, who has retained all other copyrights. For more information, please contact [email protected]. COMBATING MALIGNANT MELANOMA WITH THE MULTIFACETED SOY-DERIVED PEPTIDE LUNASIN By Christopher Paul Shidal B.S., University of Kentucky, 2008 M.S., University of Louisville, 2014 A Dissertation Submitted to the Faculty of the School of Medicine of the University of Louisville In Partial Fulfillment of the Requirements For the Degree of Doctor of Philosophy in Pharmacology and Toxicology Department of Pharmacology and Toxicology University of Louisville Louisville, KY May 2017 COMBATING MALIGNANT MELANOMA WITH THE MULTIFACETED SOY-DERIVED PEPTIDE LUNASIN By Christopher Paul Shidal A Dissertation Approved on April 24, 2017 By the following Dissertation Committee: _______________________________________ Keith R. Davis, PhD _______________________________________ J. Christopher States, PhD _______________________________________ Brian P. Ceresa, PhD _______________________________________ Kavitha Yaddanapudi, PhD _______________________________________ Geoffrey J. Clark, PhD ii ACKNOWLEDGMENTS I would like to thank my mentor, Dr. Keith R. Davis, for his guidance, patience, and support throughout this entire process. I would like to thank the committee members who agreed to serve on my graduate committee and offered invaluable advice and support. I would also like to acknowledge Christiane Hassel at the IU Flow Cytometry Core, Jim Powers at the IU Light Microscopy Imaging Center, and Sue Childress at the IU Medical Sciences program for their technical support and training used throughout this dissertation. I extend a big thank you to all of my lab mates throughout the years; Elizabeth McConnell, Banu Vuyyuri, Numan Al-Rayaan, Bharat Devapatala, Calvin Koukam, and Amanda Lasnik for their friendship, training, and dedication to developing me as a scientist. Finally, I wish to thank all of my friends and family that have endured this journey with me, and especially my fiancée, Lauren Jones, for her unconditional love and unwavering support. iii ABSTRACT COMBATING MALIGNANT MELANOMA WITH THE MULTIFACETED SOY-DERIVED PEPTIDE LUNASIN Christopher P. Shidal April 24, 2017 Lunasin is a 44 amino acid peptide that has been shown to have cancer chemopreventative and chemotherapeutic properties. This study investigated the potential utility of Lunasin as a chemotherapeutic in melanomas. Studies showed that Lunasin had little activity against established melanoma cell lines using adherent culture methods; however, Lunasin’s in vitro activity was significantly higher in non- adherent colony-forming assays and oncosphere formation. These results led to the investigation of whether or not Lunasin has selective effects on cancer initiating cells (CIC) that are known to be present in melanomas. It was revealed that Lunasin selectively inhibited the proliferation of high-ALDH expressing CICs, and prevented oncosphere formation. In vitro results were extended into mouse xenograft studies using parental cells and isolated CICs. Lunasin significantly inhibited tumor growth in both cases, with the highest inhibition being observed in tumors initiated by CICs while achieving an excellent safety profile. Lunasin reduced the invasive potential of CICs in vitro and in an in vivo experimental metastasis model. Mechanistic studies revealed that Lunasin may disrupt integrin signaling by inhibiting phosphorylations of the intracellular kinase FAK as well as altering the PI3K/AKT axis. Additionally, it was demonstrated that histone acetylation in H3 and H4 core histone are significantly altered in CICs treated with Lunasin. While histone acetylation is potentially involved in Lunasin’s anticancer activity, the effects seen in these studies are mainly integrin-driven. These studies demonstrate that Lunasin has activity against putative CICs, and that Lunasin has potential utility as a therapeutic in treating malignant melanomas. iv TABLE OF CONTENTS PAGE ACKNOWLEDGEMENTS…………………………………………………………………………….....iii ABSTRACT…………………………………………………………………………………………….....iv LIST OF FIGURES………………………………………………….………………………………….....ix CHAPTER 1. INTRODUCTION…………………………………………………………………………………….....1 1.1. Background and rationale for the study...……………………………………………………...…..1 1.1.1.1. Lunasin as an anticancer agent……...…………..……..………….……....……...……1 1.1.1.2. Integrins as a therapeutic target in melanoma patients…..……………………………5 1.1.1.3. Melanoma and the presence of melanoma stem cells…………...………………….....8 1.1.1.4. Traditional approaches to treating melanomas and future perspectives..…...….…....12 1.2. Specific aims and goals of the dissertation……………………………………………………….14 1.2.1.1. Identify the mechanisms in which Lunasin exerts its anticancer effects in melanoma…………………………………………………………………………….14 1.2.1.2. Evaluate the interaction between Lunasin and integrin subunits…………...………..15 1.2.1.3. Investigate the antimetastatic effects of Lunasin……...…...……...…………………16 2. EXPERIMENTAL PROCEDURES AND METHODOLOGY…………..……………………...…….17 2.1. Isolation and purification of Lunasin…………………………………………...………………...17 2.2. Cell culture and reagents…………………………………………………………………….……18 2.3. Proliferation assays……………………………………………………………………………….19 2.4. Soft agar colony forming assays………………………………………………………………….19 2.5. ALDEFLUOR staining………………...…………………………………………………………20 2.6. Flow Cytometry (Apoptosis)……………………………………………………………………..20 2.7. Flow cytometry (Cell Cycle)……………………………………………………………………..22 2.8. Fluorescence-assisted cell sorting (FACS)……………………………………………………….22 v 2.9. Formation of multicellular oncospheres………………………………………………………….22 2.10. In vivo xenograft model…………………………………………………………………………..23 2.11. SDS-PAGE and immunoblot……………………………………………………………………..25 2.12. Non-steroidal anti-inflammatory drug (NSAID) toxicological panel and complete blood count (CBC)……………………………………………………………………………………………..26 2.13. In vivo Limiting Dilution Assay and ALDH Activity in Primary Tumors………………………27 2.14. Β-Galactosidase staining………………………………………………………………………….27 2.15. Liquid overlay generation of multicellular tumor spheres………………………………………..28 2.16. Microarray………………………………………………………………………………………..28 2.17. Immunofluorescence……………………………………………………………………………..28 2.18. Proximity ligation assay…………………………………………………………………………..29 2.19. Transwell invasion assay…………………………………………………………………………30 2.20. Murine model of experimental metastasis………………………………………………………..30 2.21. Histology………………………………………………………………………………………….31 2.22. Differentiation of ALDHhigh cells…………………………………………………………………31 2.23. Statistical analysis………………………………………………………………………………...31 3. LUNASIN IS A NOVEL THERAPEUTIC FOR TARGETING MELANOMA STEM CELLS….….33 3.1. Introduction…………………………………………………………………………………….…33 3.2. Materials and methods……………………………………………………………………………34 3.3. Results…………………………………………………………………………………………….36 3.3.1.1. Lunasin inhibits anchorage-independent growth in human melanoma cell lines …...36 3.3.1.2. Lunasin inhibits tumor growth of melanoma cells in vivo ………………………….36 3.3.1.3. Lunasin reduces the melanoma CIC subpopulation in established cell lines ……….38 3.3.1.4. Lunasin suppresses the functional properties of melanoma CICs ………...…...……41 3.3.1.5. Lunasin limits in vivo growth of tumors initiated by melanoma CIC-enriched ALDHhigh cells ……………………………………………………………...…..……41 3.3.1.6. Limiting dilution assays demonstrate differential growth patterns between ALDHhigh and ALDHlow phenotypes………………………………………...…………………..44 vi 3.3.1.7. CIC markers are heterogeneously expressed in different melanoma cell lines...……46 3.3.1.8. Lunasin induces expression of differentiation markers in melanoma CICs…………48 3.3.1.9. Lunasin did not induce a significant senescent response in ALDHhigh melanoma cells…………………………………………………………………………………..50 3.3.1.10. Lunasin may enhance the efficacy of vemurafenib in vemurafenib-resistant melanomas……...…………………………………………………………………….53 3.4. Discussion………………………………………………………………………………………...57 4. LUNASIN REDUCES THE METASTATIC POTENTIAL OF MALIGNANT MELANOMAS BY INHIBITING INTEGRIN SIGNALING AND ALTERING HISTONE ACETYLATION………..…63 4.1. Introduction………………………………………………………………………………………63 4.2. Materials and methods……………………………………………………………………………66 4.3. Results…………………………………………………………………………………………….69 4.3.1.1. Microarray reveals Lunasin-targeted genes and identifies a unique gene signature in high ALDH melanoma cells compared to parental cells …………………...………….69 4.3.1.2. Lunasin uptake correlates with expression of αV integrin subunits…….………..…..85 4.3.1.3. B16-F10 CIC populations were reduced with Lunasin treatment……………………86 4.3.1.4. Lunasin inhibits invasion of ALDHhigh melanoma stem
Load more

Recommended publications
  • The B Vitamins Nicotinamide (B3) and Riboflavin (B2)
    The B Vitamins Nicotinamide (B3) and Riboflavin (B2) Stimulate Metamorphosis in Larvae of the Deposit- Feeding Polychaete Capitella teleta: Implications for a Sensory Ligand-Gated Ion Channel Robert T. Burns1*, Jan A. Pechenik1, William J. Biggers2, Gia Scavo2, Christopher Lehman2 1 Department of Biology, Tufts University, Medford, Massachusetts, United States of America, 2 Department of Biology, Wilkes University, Wilkes-Barre, Pennsylvania, United States of America Abstract Marine sediments can contain B vitamins, presumably incorporated from settled, decaying phytoplankton and microorganisms associated with decomposition. Because B vitamins may be advantageous for the energetically intensive processes of metamorphosis, post-metamorphic growth, and reproduction, we tested several B vitamins to determine if they would stimulate larvae of the deposit-feeding polychaete Capitella teleta to settle and metamorphose. Nicotinamide and riboflavin individually stimulated larvae of C. teleta to settle and metamorphose, generally within 1–2 hours at nicotinamide concentrations as low as 3 mM and riboflavin concentrations as low as 50 mM. More than 80% of the larvae metamorphosed within 30 minutes at a nicotinamide concentration of 7 mM. The pyridine channel agonist pyrazinecarboxamide also stimulated metamorphosis at very low concentrations. In contrast, neither lumichrome, thiamine HCl, pyridoxine HCl, nor vitamin B12 stimulated larvae of C. teleta to metamorphose at concentrations as high as 500 mM. Larvae also did not metamorphose in response to either nicotinamide or pyrazinecarboxamide in calcium-free seawater or with the addition of 4-acetylpyridine, a competitive inhibitor of the pyridine receptor. Together, these results suggest that larvae of C. teleta are responding to nicotinamide and riboflavin via a chemosensory pyridine receptor similar to that previously reported to be present on crayfish chela and involved with food recognition.
    [Show full text]
  • Neural Stem Cell-Derived Exosomes Revert HFD-Dependent Memory Impairment Via CREB-BDNF Signalling
    International Journal of Molecular Sciences Article Neural Stem Cell-Derived Exosomes Revert HFD-Dependent Memory Impairment via CREB-BDNF Signalling Matteo Spinelli 1, Francesca Natale 1,2, Marco Rinaudo 1, Lucia Leone 1,2, Daniele Mezzogori 1, Salvatore Fusco 1,2,* and Claudio Grassi 1,2 1 Department of Neuroscience, Università Cattolica del Sacro Cuore, 00168 Rome, Italy; [email protected] (M.S.); [email protected] (F.N.); [email protected] (M.R.); [email protected] (L.L.); [email protected] (D.M.); [email protected] (C.G.) 2 Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy * Correspondence: [email protected] Received: 6 October 2020; Accepted: 25 November 2020; Published: 26 November 2020 Abstract: Overnutrition and metabolic disorders impair cognitive functions through molecular mechanisms still poorly understood. In mice fed with a high fat diet (HFD) we analysed the expression of synaptic plasticity-related genes and the activation of cAMP response element-binding protein (CREB)-brain-derived neurotrophic factor (BDNF)-tropomyosin receptor kinase B (TrkB) signalling. We found that a HFD inhibited both CREB phosphorylation and the expression of a set of CREB target genes in the hippocampus. The intranasal administration of neural stem cell (NSC)-derived exosomes (exo-NSC) epigenetically restored the transcription of Bdnf, nNOS, Sirt1, Egr3, and RelA genes by inducing the recruitment of CREB on their regulatory sequences. Finally, exo-NSC administration rescued both BDNF signalling and memory in HFD mice. Collectively, our findings highlight novel mechanisms underlying HFD-related memory impairment and provide evidence of the potential therapeutic effect of exo-NSC against metabolic disease-related cognitive decline.
    [Show full text]
  • Oup Radres Rrz001 289..297 ++
    Journal of Radiation Research, Vol. 60, No. 3, 2019, pp. 289–297 doi: 10.1093/jrr/rrz001 Advance Access Publication: 26 February 2019 Ionizing radiation affects the composition of the proteome of extracellular vesicles released by head-and-neck cancer cells in vitro Agata Abramowicz1, Anna Wojakowska1, Lukasz Marczak2, Malgorzata Lysek-Gladysinska3, Mateusz Smolarz1, Michael D. Story4, Joanna Polanska5, Piotr Widlak1 and Monika Pietrowska1,* 1Center for Translational Research and Molecular Biology of Cancer, Maria Sklodowska–Curie Institute–Oncology Center, Gliwice Branch, ul. Wybrzeze Armii Krajowej 15, 44-101 Gliwice, Poland 2Institute of Bioorganic Chemistry, Polish Academy of Sciences, ul. Noskowskiego 12/14, 61-704 Poznan, Poland 3The Jan Kochanowski University in Kielce, Institute of Biology, Department of Cell Biology and Electron Microscopy, ul. Swietokrzyska 15, 25-406 Kielce, Poland 4University of Texas Southwestern Medical Center, Department of Radiation Oncology, Division of Molecular Radiation Biology, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA 5Faculty of Automatic Control, Electronics and Computer Science, Silesian University of Technology, ul. Akademicka 16, 44-100 Gliwice, Poland *Corresponding author. Center for Translational Research and Molecular Biology of Cancer, Maria Sklodowska–Curie Institute–Oncology Center, Gliwice Branch, ul. Wybrzeze Armii Krajowej 15, 44-101 Gliwice, Poland. Tel: +0048-32-278-9627; Fax: +0048-32-278-9840; Email: [email protected] (Received 29 August 2018; revised 7 November 2018; editorial decision 8 January 2019) ABSTRACT Exosomes and other extracellular vesicles are key players in cell-to-cell communication, and it has been proposed that they are involved in different aspects of the response to ionizing radiation, including transmitting the radiation-induced bystander effect and mediating radioresistance.
    [Show full text]
  • Neurotransmitters-Drugs Andbrain Function.Pdf
    Neurotransmitters, Drugs and Brain Function. Edited by Roy Webster Copyright & 2001 John Wiley & Sons Ltd ISBN: Hardback 0-471-97819-1 Paperback 0-471-98586-4 Electronic 0-470-84657-7 Neurotransmitters, Drugs and Brain Function Neurotransmitters, Drugs and Brain Function. Edited by Roy Webster Copyright & 2001 John Wiley & Sons Ltd ISBN: Hardback 0-471-97819-1 Paperback 0-471-98586-4 Electronic 0-470-84657-7 Neurotransmitters, Drugs and Brain Function Edited by R. A. Webster Department of Pharmacology, University College London, UK JOHN WILEY & SONS, LTD Chichester Á New York Á Weinheim Á Brisbane Á Singapore Á Toronto Neurotransmitters, Drugs and Brain Function. Edited by Roy Webster Copyright & 2001 John Wiley & Sons Ltd ISBN: Hardback 0-471-97819-1 Paperback 0-471-98586-4 Electronic 0-470-84657-7 Copyright # 2001 by John Wiley & Sons Ltd. Bans Lane, Chichester, West Sussex PO19 1UD, UK National 01243 779777 International ++44) 1243 779777 e-mail +for orders and customer service enquiries): [email protected] Visit our Home Page on: http://www.wiley.co.uk or http://www.wiley.com All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, scanning or otherwise, except under the terms of the Copyright, Designs and Patents Act 1988 or under the terms of a licence issued by the Copyright Licensing Agency Ltd, 90 Tottenham Court Road, London W1P0LP,UK, without the permission in writing of the publisher. Other Wiley Editorial Oces John Wiley & Sons, Inc., 605 Third Avenue, New York, NY 10158-0012, USA WILEY-VCH Verlag GmbH, Pappelallee 3, D-69469 Weinheim, Germany John Wiley & Sons Australia, Ltd.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Supporting Information
    Supporting Information Figure S1. The functionality of the tagged Arp6 and Swr1 was confirmed by monitoring cell growth and sensitivity to hydeoxyurea (HU). Five-fold serial dilutions of each strain were plated on YPD with or without 50 mM HU and incubated at 30°C or 37°C for 3 days. Figure S2. Localization of Arp6 and Swr1 on chromosome 3. The binding of Arp6-FLAG (top), Swr1-FLAG (middle), and Arp6-FLAG in swr1 cells (bottom) are compared. The position of Tel 3L, Tel 3R, CEN3, and the RP gene are shown under the panels. Figure S3. Localization of Arp6 and Swr1 on chromosome 4. The binding of Arp6-FLAG (top), Swr1-FLAG (middle), and Arp6-FLAG in swr1 cells (bottom) in the whole chromosome region are compared. The position of Tel 4L, Tel 4R, CEN4, SWR1, and RP genes are shown under the panels. Figure S4. Localization of Arp6 and Swr1 on the region including the SWR1 gene of chromosome 4. The binding of Arp6- FLAG (top), Swr1-FLAG (middle), and Arp6-FLAG in swr1 cells (bottom) are compared. The position and orientation of the SWR1 gene is shown. Figure S5. Localization of Arp6 and Swr1 on chromosome 5. The binding of Arp6-FLAG (top), Swr1-FLAG (middle), and Arp6-FLAG in swr1 cells (bottom) are compared. The position of Tel 5L, Tel 5R, CEN5, and the RP genes are shown under the panels. Figure S6. Preferential localization of Arp6 and Swr1 in the 5′ end of genes. Vertical bars represent the binding ratio of proteins in each locus.
    [Show full text]
  • Investigation of Candidate Genes and Mechanisms Underlying Obesity
    Prashanth et al. BMC Endocrine Disorders (2021) 21:80 https://doi.org/10.1186/s12902-021-00718-5 RESEARCH ARTICLE Open Access Investigation of candidate genes and mechanisms underlying obesity associated type 2 diabetes mellitus using bioinformatics analysis and screening of small drug molecules G. Prashanth1 , Basavaraj Vastrad2 , Anandkumar Tengli3 , Chanabasayya Vastrad4* and Iranna Kotturshetti5 Abstract Background: Obesity associated type 2 diabetes mellitus is a metabolic disorder ; however, the etiology of obesity associated type 2 diabetes mellitus remains largely unknown. There is an urgent need to further broaden the understanding of the molecular mechanism associated in obesity associated type 2 diabetes mellitus. Methods: To screen the differentially expressed genes (DEGs) that might play essential roles in obesity associated type 2 diabetes mellitus, the publicly available expression profiling by high throughput sequencing data (GSE143319) was downloaded and screened for DEGs. Then, Gene Ontology (GO) and REACTOME pathway enrichment analysis were performed. The protein - protein interaction network, miRNA - target genes regulatory network and TF-target gene regulatory network were constructed and analyzed for identification of hub and target genes. The hub genes were validated by receiver operating characteristic (ROC) curve analysis and RT- PCR analysis. Finally, a molecular docking study was performed on over expressed proteins to predict the target small drug molecules. Results: A total of 820 DEGs were identified between
    [Show full text]
  • Beyond Desensitization: Physiological Relevance of Arrestin-Dependent Signaling
    0031-6997/10/6202-305–330$20.00 PHARMACOLOGICAL REVIEWS Vol. 62, No. 2 U.S. Government work not protected by U.S. copyright 2436/3586110 Pharmacol Rev 62:305–330, 2010 Printed in U.S.A. ASSOCIATE EDITOR: DAVID R. SIBLEY Beyond Desensitization: Physiological Relevance of Arrestin-Dependent Signaling LOUIS M. LUTTRELL AND DIANE GESTY-PALMER Departments of Medicine and Biochemistry & Molecular Biology, Medical University of South Carolina (L.M.L.) and the Ralph H. Johnson Veterans Affairs Medical Center (L.M.L.), Charleston, South Carolina; and Department of Medicine, Duke University Medical Center (D.G.-P.) and the Durham Veterans Affairs Medical Center (D.G.-P.), Durham, North Carolina Abstract ................................................................................ 305 I. Introduction............................................................................. 306 II. The duality of arrestin function ........................................................... 307 A. Arrestin-dependent desensitization and endocytosis...................................... 307 B. Arrestins as signal transducers ........................................................ 308 III. Arrestin signaling in vitro ................................................................ 310 A. Diversity in arrestin signaling ......................................................... 310 B. Receptor desensitization and second messenger production ............................... 311 C. Receptor endocytosis and vesicle trafficking ............................................
    [Show full text]
  • Understanding Allergic Multimorbidity Within the Non-Eosinophilic
    University of Groningen Understanding allergic multimorbidity within the non-eosinophilic interactome Aguilar, Daniel; Lemonnier, Nathanael; Koppelman, Gerard H; Melén, Erik; Oliva, Baldo; Pinart, Mariona; Guerra, Stefano; Bousquet, Jean; Anto, Josep M Published in: PLoS ONE DOI: 10.1371/journal.pone.0224448 IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 2019 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): Aguilar, D., Lemonnier, N., Koppelman, G. H., Melén, E., Oliva, B., Pinart, M., Guerra, S., Bousquet, J., & Anto, J. M. (2019). Understanding allergic multimorbidity within the non-eosinophilic interactome. PLoS ONE, 14(11), [e0224448]. https://doi.org/10.1371/journal.pone.0224448 Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Download date: 26-12-2020 RESEARCH ARTICLE Understanding allergic multimorbidity within the non-eosinophilic interactome 1,2,3 4 5,6 7 Daniel AguilarID *, Nathanael LemonnierID , Gerard H.
    [Show full text]
  • Ncounter® Mouse Autoimmune Profiling Panel - Gene and Probe Details
    nCounter® Mouse AutoImmune Profiling Panel - Gene and Probe Details Official Symbol Accession Alias / Previous Symbol Official Full Name Other targets or Isoform Information AW208573,CD143,expressed sequence AW208573,MGD-MRK- Ace NM_009598.1 1032,MGI:2144508 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 2610036I19Rik,2610510L13Rik,Acinus,apoptotic chromatin condensation inducer in the nucleus,C79325,expressed sequence C79325,MGI:1913562,MGI:1919776,MGI:2145862,mKIAA0670,RIKEN cDNA Acin1 NM_001085472.2 2610036I19 gene,RIKEN cDNA 2610510L13 gene apoptotic chromatin condensation inducer 1 Acp5 NM_001102405.1 MGD-MRK-1052,TRACP,TRAP acid phosphatase 5, tartrate resistant 2310066K23Rik,AA960180,AI851923,Arp1b,expressed sequence AA960180,expressed sequence AI851923,MGI:2138136,MGI:2138359,RIKEN Actr1b NM_146107.2 cDNA 2310066K23 gene ARP1 actin-related protein 1B, centractin beta Adam17 NM_001277266.1 CD156b,Tace,tumor necrosis factor-alpha converting enzyme a disintegrin and metallopeptidase domain 17 ADAR1,Adar1p110,Adar1p150,AV242451,expressed sequence Adar NM_001038587.3 AV242451,MGI:2139942,mZaADAR adenosine deaminase, RNA-specific Adora2a NM_009630.2 A2AAR,A2aR,A2a, Rs,AA2AR,MGD-MRK-16163 adenosine A2a receptor Ager NM_007425.2 RAGE advanced glycosylation end product-specific receptor AI265500,angiotensin precursor,Aogen,expressed sequence AI265500,MGD- Agt NM_007428.3 MRK-1192,MGI:2142488,Serpina8 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Ah,Ahh,Ahre,aromatic hydrocarbon responsiveness,aryl hydrocarbon
    [Show full text]
  • Table SI. the Predicted Targets of Mir-221-3P with Targetscan Database
    Table SI. The predicted targets of miR-221-3p with TargetScan database. Target gene Representative transcript Gene name VAPB ENST00000395802.3 VAMP (vesicle-associated membrane protein)-associated protein B and C TMSB15B ENST00000540220.1 Thymosin beta 15B TFG ENST00000240851.4 TRK-fused gene HECTD2 ENST00000371667.1 HECT domain containing E3 ubiquitin protein ligase 2 CLVS2 ENST00000275162.5 Clavesin 2 PAIP1 ENST00000514514.1 poly(A) binding protein interacting protein 1 MIDN ENST00000591446.2 Midnolin AGFG1 ENST00000310078.8 ArfGAP with FG repeats 1 HMBOX1 ENST00000397358.3 Homeobox containing 1 MYLIP ENST00000349606.4 Myosin regulatory light chain interacting protein SEC62 ENST00000337002.4 SEC62 homolog (S. cerevisiae) TMCC1 ENST00000432054.2 Transmembrane and coiled-coil domain family 1 PHACTR4 ENST00000373839.3 Phosphatase and actin regulator 4 AIDA ENST00000340020.6 Axin interactor, dorsalization associated BEAN1 ENST00000299694.8 Brain expressed, associated with NEDD4, 1 AMMECR1 ENST00000262844.5 Alport syndrome, midface hypoplasia and elliptocytosis chro- mosomal region gene 1 EIF3J ENST00000261868.5 Eukaryotic translation initiation factor 3, subunit J SMARCA5 ENST00000283131.3 SWI/SNF related, actin dependent regulator of chromatin, subfamily a, member 5 TCF12 ENST00000267811.5 Transcription factor 12 PNO1 ENST00000263657.2 Partner of NOB1 homolog (S. cerevisiae) ZBTB37 ENST00000367701.5 Zinc finger and BTB domain containing 37 FOS ENST00000303562.4 FBJ murine osteosarcoma viral oncogene homolog ZNF385A ENST00000551109.1 Zinc
    [Show full text]
  • This Thesis Has Been Submitted in Fulfilment of the Requirements for a Postgraduate Degree (E.G
    This thesis has been submitted in fulfilment of the requirements for a postgraduate degree (e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following terms and conditions of use: This work is protected by copyright and other intellectual property rights, which are retained by the thesis author, unless otherwise stated. A copy can be downloaded for personal non-commercial research or study, without prior permission or charge. This thesis cannot be reproduced or quoted extensively from without first obtaining permission in writing from the author. The content must not be changed in any way or sold commercially in any format or medium without the formal permission of the author. When referring to this work, full bibliographic details including the author, title, awarding institution and date of the thesis must be given. The CX3CR1/CX3CL1 Axis Drives the Migration and Maturation of Oligodendroglia in the Central Nervous System Catriona Ford Thesis Submitted for the Degree of Doctor of Philosophy The University of Edinburgh 2017 Abstract In the central nervous system, the axons of neurons are protected from damage and aided in electrical conductivity by the myelin sheath, a complex of proteins and lipids formed by oligodendrocytes. Loss or damage to the myelin sheath may result in impairment of electrical axonal conduction and eventually to neuronal death. Such demyelination is responsible, at least in part, for the disabling neurodegeneration observed in pathologies such as Multiple Sclerosis (MS) and Spinal Cord Injury. In the regenerative process of remyelination, oligodendrocyte precursor cells (OPCs), the resident glial stem cell population of the adult CNS, migrate toward the injury site, proliferate and differentiate into adult oligodendrocytes which subsequently reform the myelin sheath.
    [Show full text]